Skip to content
Homepage
Author:
Organogenesis Holdings Inc.
Posted Date:
July 27, 2026
Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers
Organogenesis Holdings Inc.
July 27, 2026
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
Organogenesis Holdings Inc.
July 9, 2026
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
Organogenesis Holdings Inc.
July 6, 2026
